180 related articles for article (PubMed ID: 17719087)
1. Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies.
Veselovska J; Pospisilova D; Pekova S; Horvathova M; Solna R; Cmejlova J; Cmejla R; Belickova M; Mihal V; Stary J; Divoky V
Leuk Res; 2008 Mar; 32(3):369-77. PubMed ID: 17719087
[TBL] [Abstract][Full Text] [Related]
2. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
[TBL] [Abstract][Full Text] [Related]
3. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
4. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
5. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
Nakatani T; Imamura T; Ishida H; Wakaizumi K; Yamamoto T; Otabe O; Ishigami T; Adachi S; Morimoto A
Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
7. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
[TBL] [Abstract][Full Text] [Related]
9. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.
Antonioli E; Guglielmelli P; Poli G; Bogani C; Pancrazzi A; Longo G; Ponziani V; Tozzi L; Pieri L; Santini V; Bosi A; Vannucchi AM;
Haematologica; 2008 Jan; 93(1):41-8. PubMed ID: 18166784
[TBL] [Abstract][Full Text] [Related]
10. Characterization of murine JAK2V617F-positive myeloproliferative disease.
Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
[TBL] [Abstract][Full Text] [Related]
11. Influence of the assays of endogenous colony formation and serum erythropoietin on the diagnosis of polycythemia vera and essential thrombocythemia.
Mossuz P;
Semin Thromb Hemost; 2006 Apr; 32(3):246-50. PubMed ID: 16673278
[TBL] [Abstract][Full Text] [Related]
12. The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia.
Lambert JR; Gale RE; Linch DC
Br J Haematol; 2009 Apr; 145(1):128-30. PubMed ID: 19222478
[TBL] [Abstract][Full Text] [Related]
13. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
[TBL] [Abstract][Full Text] [Related]
14. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
[TBL] [Abstract][Full Text] [Related]
15. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
16. Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia.
Medeiros BC; Zhang T; Lipton JH; Kamel-Reid S
Am J Hematol; 2007 Apr; 82(4):293-4. PubMed ID: 17013813
[TBL] [Abstract][Full Text] [Related]
17. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
Hsiao HH; Yang MY; Liu YC; Lee CP; Yang WC; Liu TC; Chang CS; Lin SF
Exp Hematol; 2007 Nov; 35(11):1704-7. PubMed ID: 17920754
[TBL] [Abstract][Full Text] [Related]
18. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
Shi J; Yuan B; Hu W; Lodish H
Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
[TBL] [Abstract][Full Text] [Related]
19. Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood.
Stevenson WS; Hoyt R; Bell A; Guipponi M; Juneja S; Grigg AP; Curtis DJ; Scott HS; Szer J; Alexander WS; Tuckfield A; Roberts AW
Pathology; 2006 Aug; 38(4):336-42. PubMed ID: 16916724
[TBL] [Abstract][Full Text] [Related]
20. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.
Dupont S; Massé A; James C; Teyssandier I; Lécluse Y; Larbret F; Ugo V; Saulnier P; Koscielny S; Le Couédic JP; Casadevall N; Vainchenker W; Delhommeau F
Blood; 2007 Aug; 110(3):1013-21. PubMed ID: 17389763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
